O. V. Morozova

O. V. Morozova

Auto-generated profile, based on publicly available information

O. V. Morozova

Ural State Medical University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 January 2022 in Russian Ophthalmological Journal
Verified
Journal Article
Open access
PDF file
EBE. V. Bobykin
E. V. Bobykin
OMO. V. Morozova
O. V. Morozova
NBN. S. Beresneva
N. S. Beresneva
Macular diseases are traditionally a serious issue in ophthalmology, which has great social impact due to widespread occurrence and significant vision loss, often irreversible. Over the past few decades, the possibilities for the diagnosis and treatment of pathologies of the retina and choroid have been significantly expanded. Randomized clinical trials provided ophthalmologists with valuable information on the natural course and treatment strategies of common retinal diseases from the viewpoint of evidence-based medicine. However, due to the large number of trials conducted, it is often difficult to make an adequate choice of data to be used in daily practice. In this review, we systematize the most valuable randomized clinical trials. To this end, we selected 42 randomized clinical studies conducted between 1979 and 2019 and focused on the treatment of age-related macular degeneration (AREDS 1, AREDS 2, ANCHOR, MARINA, PrONTO, CATT, IVAN, VIEW 1, VIEW 2, EVEREST II, PLANET, SEVEN-UP, ALTAIR, HAWK, HARRIER), choroidal neovascularization of multiple etiology (myopic, post-inflammatory, angioid-streak-related, etc. — RADIANCE, REPAIR, MYRROR, MINERVA), diabetic eye lesions (diabetic retinopathy and diabetic macular edema — ETDRS, DRCR.net Protocols B, I, S and T, RISE, RIDE, VIVID-DME, VISTA-DME, MEAD, FAME), retinal vein occlusions (BVOS, CVOS, SCORE-CRVO, SCORE-BRVO, BRAVO, CRUISE, GALILEO, COPERNICUS, VIBRANT), as well as retinopathy of prematurity (CRYO-ROP, ETROP, RAINBOW). The review summarizes the main results of these studies, which confirm the effectiveness and safety of such treatment methods as antiVEGF and photodynamic therapy, retinal laser photocoagulation, cryotherapy, corticosteroids and nutraceuticals from the viewpoint of evidence-based medicine. For greater clarity, we provide a table summarizing information on each of the randomized clinical trials considered.

17 June 2021 in Russian Ophthalmological Journal
Verified
Journal Article
Open access
PDF file
VNV. V. Neroev
V. V. Neroev
OZO. V. Zaytseva
O. V. Zaytseva
EBE. V. Bobykin
E. V. Bobykin
AFA. Zh. Fursova
A. Zh. Fursova
PNP. A. Nechiporenko
P. A. Nechiporenko
RSR. M. Sutyushev
R. M. Sutyushev
Intravitreal injection (IVI) is a drug delivery method, widely used in modern ophthalmology. To increase the awareness of patients receiving treatment in the healthcare system of the Russian Federation, the Expert Council on Retinal and Optic Nerve Diseases of the Association of Ophthalmologists, an All-Russian Public Organization in 2020 proposed a leaflet “Intravitreal injections (information for patients)”.Purpose: to conduct a clinical assessment of the leaflet by multicenter anonymous surveying of patients.Material and methods. Patients who had experienced IVI treatment were asked to read the leaflet for 20 minutes and then answer 12 questions of the specially designed questionnaire. 93 patients were interviewed in clinics in Moscow, St. Petersburg, Yekaterinburg and Novosibirsk: of these, 57 (61.3%), the average age of all patients was 63.9 years, the most common diagnosis was neovascular age-related macular degeneration (52 cases, 55.9%), the experience of previous treatment ranged from 1 to 104 months.Results. The leaflet had a positive response from the patients (91.4% of the questionnaires received “excellent” and “good” ratings), 90.3% patients reported that the information contained was fully or largely consistent with their experience of IVI treatment. The overwhelming majority of respondents (88.2%) did not experience any difficulties in reading the leaflet. At the same time, the patients revealed insufficient awareness on issues related to the treatment. Also, the patients showed insufficient awareness of issues concerning their health: only 20 (21.5%) respondents could answer all five questions of the questionnaire about the understanding of the relevant information, and 31 patients (33.3%) could answer four questions. This fact emphasizes the importance of information support for the patient.Conclusion. The clinical assessment of the leaflet “Intravitreal injections (information for patients)”, which contains brief information about what the procedure is, contraindications, preparation details, symptoms of the postoperative period that require urgent assistance, allows us to recommend the leaflet for use in the clinical healthcare practice of the Russian Federation.

23 November 2021 in Acta Biomedica Scientifica
Verified
Journal Article
Open access
PDF file
EBE. V. Bobykin
E. V. Bobykin
IKI. A. Kulakova
I. A. Kulakova
OMO. V. Morozova
O. V. Morozova
VKV. Ya. Krokhalev
V. Ya. Krokhalev
Background. At present, intraocular drops of silicone oil, which is a lubricant for disposable syringes used for intravitreal injections, are being actively studied. Among the undesirable effects of their presence are patient’s complaints of visual discomfort associated with floating opacities, as well as a potential connection with episodes of intraocular inflammation and increased intraocular pressure.The aim: to assess the prevalence of silicone oil droplets in the vitreous in patients treated with multiple intravitreal injections.Materials and methods. A single-center retrospective cohort study was carried out. Inclusion criterion: treatment with multiple (at least 5) intravitreal injections of drug solutions performed according to registered indications. The study group consisted of 86 eyes of 85 patients (56 women, 29 men; age – from 36 to 89 y.o., average – 71.7 y.o.), who received an average of 13.2 injections of solutions of various drugs.Results. Drops of silicone oil were detected by biomicroscopy in 57 eyes (66.28 %) and by ultrasonography in 76 (88.37 %). The coincidence of the results of applying the methods was recorded in 73.26 % of observations. Seven (8.1 %) patients had characteristic complaints. Four patients (4.7 %) had a history of aseptic vitreitis. The hypothesis was confirmed that the possibility of silicone oil droplets getting into the vitreous increases with the number of intravitreal injections. A similar relationship was established in relation to the possibility of the appearance of characteristic complaints in patients due to the presence of drops and episodes of aseptic vitreitis.Conclusion. The release of drops of silicone oil from syringes during intravitreal injections is an urgent problem that requires further study. In the Russian Federation, the situation is aggravated by the lack of prefilled syringes with drugs approved for administration into the eye cavity, as well as the lack of syringe models designed for use in ophthalmology.